"Factor VIII" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
| Descriptor ID |
D005169
|
| MeSH Number(s) |
D12.776.124.125.350 D23.119.350
|
| Concept/Terms |
Factor VIII- Factor VIII
- Factor 8
- Coagulation Factor VIII
- Thromboplastinogen
- Blood Coagulation Factor VIII
- Factor Eight
Hyatt-C- Hyatt-C
- Hyatt C
- HyattC
- Hyate-C
- Hyate C
- HyateC
|
Below are MeSH descriptors whose meaning is more general than "Factor VIII".
Below are MeSH descriptors whose meaning is more specific than "Factor VIII".
This graph shows the total number of publications written about "Factor VIII" by people in this website by year, and whether "Factor VIII" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 5 | 3 | 8 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 1 | 5 |
| 2021 | 1 | 8 | 9 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 3 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor VIII" by people in Profiles.
-
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
-
RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
-
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
-
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
-
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
-
Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
-
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
-
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
-
An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
-
A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.